Michael G. Hanna Jr PhD
Immunology and Microbiology, Research and Clinical Research
Baltimore, Maryland, United States of America
Connect with the speaker?
Michael G. Hanna, Jr., Ph.D., a pioneer in cancer immunotherapy, co-founded Vaccinogen in 2007 and served as Chairman and CEO. Currently, Dr. Hanna is Chairman Emeritus of the Company’s Board of Directors.
Dr. Hanna is the discoverer and developer of Vaccinogen’s lead product, OncoVAX®, an autologous vaccine designed to elicit a specifc immune response against minimal residual disease after surgery. Vaccinogen believes OncoVAX® is the first product to show a significant reduction in recurrence of disease in stage II colon cancer patients.
Dr. Hanna is the discoverer and developer of Vaccinogen’s lead product, OncoVAX®, an autologous vaccine designed to elicit a specifc immune response against minimal residual disease after surgery. Vaccinogen believes OncoVAX® is the first product to show a significant reduction in recurrence of disease in stage II colon cancer patients.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)
Quick Links
Connect With Us
Awards & Recognitions
- 50 Division Street, Suite 501,
- Somerville, NJ 08876
- support@emedevents.com